Effective treatment of the central nervous system in lysosomal storage diseases: Save that brain!

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 6, 2003, Pages 361-363

  Peters, Charles ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM2; GANGLIOSIDE GM3; GENE PRODUCT; LEVO IDURONIDASE; RECOMBINANT DNA;

CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; EDITORIAL; ENZYME REPLACEMENT; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC CELL; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; SANFILIPPO SYNDROME; TREATMENT OUTCOME;

EID: 0345871053     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2003.09.003     Document Type: Editorial

References (39)

1. Fratantoni JC, Hall CW, Neufeld EF. The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation. Proc Natl Acad Sci U S A 1969;64:360-6.
2. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991;60:257-80.
3. Bou-Gharios G, Abraham D, Olsen I. Lysosomal storage diseases: mechanisms of enzyme replacement therapy. Histochem J 1993;25:593-605.
4. Chao HH-J, Waheed A, Pohlmann R, Hille A, von Figura K. Mannose-6-phosphate receptor dependent secretion of lysosomal enzymes. EMBO J 1990;9:3507-13.
5. Pfeffer SR. Targeting of proteins to the lysosome. Curr Topic Microbiol Immunol 1991;170:43-65.
6. Rodman JS, Mercer RW, Stahl PD. Endocytosis and trancytosis. Curr Opin Cell Biol 1990;2:664-72.
7. Jenkins HG, Martin J, Dean MF. Receptor-mediated uptake of b-glucuronidase into primary astrocytes and C6 glioma cells from rat brain. Brain Res 1988;462:265-74.
8. Olsen I, Dean MF, Harris G, Muir H. Direct transfer of a lysosomal enzyme from lymphoid cells to deficient fibroblasts. Nature 1981;291:244-7.
9. Olsen I, Oliver T, Muir H, Smith R, Partridge T. Role of cell adhesion in contact-dependent transfer of a lysosomal enzyme from lymphocytes to fibroblasts. J Cell Sci 1986;85:231-44.
10. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. Vol. 3. New York, NY: McGraw-Hill; 2001:3421-52.
11. Perry VH, Gordon S. Macrophages and the nervous system. Int Rev Cytol 1991;125:203-44.
12. Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for resonstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995;4:385-92.
13. Giulian D. Ameboid microglia as effectors of inflammation in the central nervous system. J Neurosci Res 1987;18:155-71.
14. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1991;1:97-105.
15. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 1997;90:986-93.
16. Yeager AM, Shinn C, Hart C, Pardoll DM. Repopulation by donor-derived macrophages in the murine central nervous system (CNS) after congenic bone marrow transplantation (BMT): a quantitative study. Blood 1992;80(suppl 1):269a.
17. Brieder MA, Shull RM, Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am J Pathol 1989;134:677-92.
18. Shull RM, Hastings NE, Selcer RE, Jones JB, Smith JR, Cullen WC, et al. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system. J Clin Invest 1987;9:435-43.
19. Shull RM, Brieder MA, Constantopoulos G. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease model. Pediatr Res 1988;24:347-52.
20. Clarke LA, Russell CS, Pownall S, Warrington CL, Borowski A, Dimmick JE, et al. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-IDUA gene. Hum Mol Genet 1997;6:503-11.
21. Russell C, Hendson G, Jevon G, Matlock T, Yu J, Aklujkar M, et al. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 1998;53:349-61.
22. Hobbs JR, Hugh-Jones K, Barrett AJ, Byron N, Chambufs D, Henry K, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981;2:709-12.
23. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87:4894-902.
24. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ, et al. Hurler syndrome. II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998;91:2601-8.
25. Peters C, Orchard PJ, Defor TE, et al. Hematopoietic cell transplantation for Hurler syndrome: the University of Minnesota experience from 1983 to 2001 [abstract]. Blood 2001;98:667.
26. Staba S, Martin PL, Ciocci GH, Allison-Thacker J, Kurtzberg J. Correction of Hurler syndrome with unrelated umbilical cord blood transplantation [abstract]. Blood 2001;98:667.
27. Whitley CB, Belani KG, Chang PN, Summers CG, Blazar BR, Tsai MY, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Hum Genet 1993;46:209-18.
28. Krivit W, Sung JH, Lockman L, et al. Bone marrow transplantation for the treatment of lysosomal and peroxisomal diseases: focus on central nervous system reconstitution. In: Rich RR, Fleisher TA, Schwartz BD, eds. Principles of clinical immunology. St Louis, MO: Mosby; 1995:1852.
29. Phipps S, Mulhern R. Developmental outcome of unrelated donor bone marrow transplantation in children with Hurler syndrome. Blood 1997;89:732-4.
30. Guffon N, Souillet G, Maire, Straczek J, Guibaud P. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998;133:119-25.
31. Peters C, Shapiro EG, Krivit W. Hurler syndrome: past, present, and future. J Pediatr 1998;133:7-9.
32. Fleming DR, Henslee-Downey PJ, Ciocci G, Romand EH, Marciniak E, Munn RK, et al. The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I. Pediatr Transplant 1998;2:299-304.
33. Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant 1998;2:250-4.
34. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995;18:413-29.
35. Blaser SI, Clarke JTR, Becker LE. Neuroradiology of lysosomal disorders. Neuroimaging Clin North Am 1994;4:283-98.
36. Takahashi Y, Sukegawa K, Aoki M, Ito A, Suzuki K, Sakaguchi H, et al. Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidosis by (1)H-magnetic resonance spectroscopy before and after bone marrow transplantation. Pediatr Res 2001;49:349-55.
37. Zhaol KW, Faull KF, Kakkis ED, Neufeld EF. Carbohydrate structures of recombinant human alpha-L-IDUA secreted by Chinese hamster ovary cells. J Biol Chem 1997;272:22758-65.
38. Wraith JE. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 2001;24:245-50.
39. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8.